Global Lipids Genetics C, Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, et al
What Actually Works Heres what the current evidence shows about cagrilintide and CagriSema: Weight loss: REDEFINE 1 participants lost over 20% of body weight on average over 68 weeks meaningfully more than semaglutide alone
Athletes are paying closer attention to inflammation, hydration, tissue repair and how quickly the body can recover between workouts
Protecting your hair if you restart or change GLP-1 medications Switching from one GLP-1 medication to another, or restarting after a break, carries a theoretical risk of triggering another round of telogen effluvium, particularly if the new medication or restart leads to another phase of rapid weight loss
Treat the following as community-derived hypotheses, not validated outcomes: Hypothesis 1 Plateau breaking past retatrutide monotherapy Community framing is that adding cagrilintide engages a receptor system retatrutide does not target, which could theoretically extend weight loss past a retatrutide-monotherapy plateau
The Post and Courier
